SLC5A2 and heart failure: This view is supported by recent meta-analyses showinghighly significant reductions in hospitalization for heart failure for HFrEF [57]and for HFpEF [58, 59, 60] despite only moderate and/or non-significant largerNT-proBNP reductions with SGLT2 inhibitor treatment.